Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, NO 10, Jalale-Al-Ahmad Ave, Chamran Highway, Tehran, 1411713137, Iran.
Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
BMC Res Notes. 2024 Oct 24;17(1):319. doi: 10.1186/s13104-024-06975-6.
Sarcopenia is linked to escalating health costs, heightened risk of physical disability, diminished quality of life and an increased demand for care services. This study aimed to assess the economic impact of sarcopenia-related disability in Iran. A prevalence-based economic burden study was conducted utilizing the Population Attributable Risk (PAR) method, based on 2022 price index. Prevalence data for sarcopenia, categorized by gender and disease severity, were extracted from recent comprehensive studies. The relative risk of sarcopenia disability was determined from the most robust available evidence. Subsequently, direct medical costs, direct non-medical costs, and indirect costs for each individual with sarcopenia were computed and adjusted to 2022 values to estimate disability costs.
Taking into account the prevalence of sarcopenia and the Iranian population across various age groups, 2,192,168 adults aged ≥ 60 years with sarcopenia in Iran were included. The total PAR of sarcopenia for men and women was estimated at 49% and 28%, respectively. The cumulative direct medical costs, direct non-medical costs, and indirect costs amounted to $215.1 million, $7.76 million, and $34.1 million, respectively. Additionally, the average total economic burden of sarcopenia-related disability in Iranian population aged ≥ 60 years was estimated at $257.1 million.
肌少症与不断攀升的健康成本、更高的身体残疾风险、生活质量下降以及对护理服务需求的增加有关。本研究旨在评估伊朗肌少症相关残疾的经济影响。利用基于人群归因风险（PAR）的方法，基于 2022 年价格指数，进行了一项基于患病率的经济负担研究。从最近的综合研究中提取了按性别和疾病严重程度分类的肌少症患病率数据。根据最可靠的可用证据确定肌少症残疾的相对风险。随后，计算了每个肌少症患者的直接医疗成本、直接非医疗成本和间接成本，并调整至 2022 年的价值以估计残疾成本。
考虑到肌少症的患病率和伊朗不同年龄组的人口，纳入了 2192168 名年龄≥60 岁的伊朗肌少症成年人。男性和女性肌少症的总 PAR 分别估计为 49%和 28%。累计直接医疗成本、直接非医疗成本和间接成本分别为 2.151 亿美元、776 万美元和 3410 万美元。此外，估计年龄≥60 岁的伊朗人口中肌少症相关残疾的平均总经济负担为 2.571 亿美元。
Zotero 插件